Dec 31st 2014 - Share price - $4.40 Cash on hand - 9.4 million Total OS - 117 Million (ish) PROGRESS 1) Kevetrin - In Progress Phase 1 - Enrolling in the 10th cohort 2) Prurisol - Successful Phase 1 Completed - Comparing bio-availability b/w P and Ziagen 3) B-Absssi - Successful Phase 2b Completed - Topline data Oct 23rd - full data in 2015 to be announced 4) B-OM - IND filed in Sept 2014 and granted by FDA in Oct 2014
March 31st 2018 - Share price - .52 Cash on hand - 3.3 million Total OS - 155 Million PROGRESS 1) Kevetrin - Phase 1 Successful (Solid Tumors) 2) Kevetrin - Phase 2 Successful (Ovarian) 3) Prurisol - Phase 2a Successful (Mild - Moderate Psoriasis) 4) Prurisol - Phase 2b Completed (Moderate - Severe Psoriasis) DATA ANY DAY 5) B-OM - Phase 2 Successful (Oral Mucositis - PREVENTION) Leader in an untapped market 6) B-UP/UC - Phase 2 PoC Successful
**5 Additional late stage Human trials SUCCESSFUL - Awaiting data on a Phase 2b for Prurisol**
So to summarize - in 3.5 years IPIX was able to complete 5 SUCCESSFUL human trials and awaiting on data for a phase 2b. The share count increased by about 38 Million shares.
I'd say that is pretty flipping good in this arena. JMO
A partnership will set this company free and the share price will go to all time highs and no one will ever remember this blimp back to .40. IMO The market does not know IPIX and when it does and we can have institutional parties invest 10's of millions if not 100's of millions into our company this will stabilize and re-evaluate.
Here is the BUSINESS DEV portion of the last Q:
Quote: Business Development Activities
The Company is engaged in discussions and negotiations regarding the out-licensing of its mid-stage, first-in-class clinical assets to global and/or specialty pharmaceutical companies who have expressed an interest in one or more assets in our pipeline. Successfully securing partnerships would afford the Company access to immediate and potentially recurring sources of non-dilutive capital, including upfront fees, milestone-based payments and tiered royalties.
Recently, we released results from our completed Phase 2 Brilacidin study on Oral Mucositis. The results have attracted inquiries, additional confidential disclosure agreements, and discussions with pharmaceutical companies
News 
Market Data 
Discover 
